BUSINESS
MTPC’s SGLT-2 Inhibitor Canagliflozin Now No. 1 in Prescription Share in US, Overtaking Januvia
Michihiro Tsuchiya, president of Mitsubishi Tanabe Pharma Corporation (MTPC), reported at a press conference in Tokyo on August 30 that the company’s sodium glucose co-transporter-2 (SGLT-2) inhibitor canagliflozin (US brand name: INVOKANA) has overtaken the dipeptidyl peptidase-4 (DPP-4) inhibitor Januvia…
To read the full story
BUSINESS
- AG Price Parity Plan Stokes Industry Fears of Patient, Pharmacy Defections
December 12, 2025
- Kyowa Kirin Names Abdul Mullick as Next CEO from March 2026
December 12, 2025
- Regeneron Files Libtayo for Squamous Cell Carcinoma in Japan
December 12, 2025
- Chugai to Donate 100 Million Yen to Support Nobel Laureate Sakaguchi’s Research
December 12, 2025
- Regeneron Lines Up 5 Late-Stage Assets for Japan: Commercial Head
December 11, 2025
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…





